肺癌患者外周血癌胚抗原、糖类抗原水平与肺癌分期、转移及预后的关系

目的：探讨肺癌患者外周血癌胚抗原（CEA）、糖类抗原（CA19-9、CA125、CA15-3）水平与肿4瘤分期、转移及预后的关系。方法：用IMMULITE酶放大化学发光免疫分析法检测肺癌、肺部良性疾病和健康对照者各30例外周Jb-CEA、CA19-9、CA125、CA15-3的水平。患者随访2年。结果：肺癌患者外周Jb-CEA、CA125、CA15-3水平高于肺部良性疾病患者及健康对照者，差异有显著性（P〈0．05或P〈0．01）；肺癌患者血CA19-9水平与健康对照者比较差异有显著性（P〈0．05），与肺部良性疾病患者比较差异无显著性。不同分期肿瘤患者间血清CEA、糖类抗原的水平差异无显著性。CEA和CA125呈阳性的肺癌患者转移、复发的机率明显高于阴性患者，其差异有显著性（P〈0．01），在随访期间共有14住复发或转移肺癌患者死亡。血清CEA阳性患者的预后明显差于阴性患者，两者生存率比较差异有显著性（P〈0．05）。结论：外周血CEA、糖类抗原（CA125）水平的动态检测对肺癌的转移和预后判断有一定的临床意义。

Relationship between the level of serum carcinoembryonic antigen and carbohydrate antigen in staging, metastasis and prognosis of lung cancer

Objective:To study the value of serum carcinoembryonic antigen(CEA) and carbohydrate antigens(CA15-3,CA19-9 and CA125) in staging,metastasis and prognosis of patients with lung cancer.Methods:The level of CEA,CA15-3,CA19-9 and CA125 were measured in 30 lung cancer,30 lung benign disease and 30 healthy controls with IMMULITE enzyme amplification chemiluminescence immunoassay system.All patients were followed up for 2 years.Results:The level of CEA,CA15-3 and CA125 in patients with lung cancer was significantly higher than that of pulmonary benign diseases(P<0.05) and healthy controls(P <0.01).The level of CA19-9 in patients with lung cancer was significantly higher than that of pulmonary benign diseases(P<0.01),but had no significant difference when it was compared with pulmonary benign diseases.There had no significant difference in CEA,CA15-3,CA19-9 and CA125 in different stages of lung caner.The possibility of metastasis and recurrence was significantly higher for lung cancer patients with positive CEA and CA125 than those with negative CEA and CA125(P<0.01).During the follow-up period,there were 14 patients died of recurrence or metastasis.The prognosis of patients with positive CEA was worse than those with negative CEA,and there was significant difference in survival rate(P<0.05).Conclusion:The serum CEA and carbohydrate antigens CA125 are valuable in metastasis and prognosis of patients with lung cancer.